A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

NCT07694765 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Tumors

Interventions

DRUG: LM-364 for injection
DRUG: Tislelizumab

Sponsor

LaNova Medicines Limited